RhumbLine Advisers
ASMB icon

RhumbLine Advisers’s Assembly Biosciences ASMB Stock Holding History

RhumbLine Advisers’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.27K Hold
190
– – ﹤0.01% 3874
2025
Q4 		$6.46K Hold
190
– – ﹤0.01% 3910
2025
Q3 		$4.86K Hold
190
– – ﹤0.01% 3917
2025
Q2 		$3.44K Hold
190
– – ﹤0.01% 3948
2025
Q1 		$1.82K Hold
190
– – ﹤0.01% 3992
2024
Q4 		$3K Hold
190
– – ﹤0.01% 4004
2024
Q3 		$2.88K Hold
190
– – ﹤0.01% 4038
2024
Q2 		$2.61K Sell
190
-9
-5% -$128 ﹤0.01% 4161
2024
Q1 		$2.65K Sell
199
-1
-0.5% -$12 ﹤0.01% 4063
2023
Q4 		$1.97K Hold
200
– – ﹤0.01% 4095
2023
Q3 		$2.12K Hold
200
– – ﹤0.01% 4105
2023
Q2 		$2.76K Buy
+200
New +$2.46K ﹤0.01% 4172
2021
Q2 		– Sell
-3,593
Closed -$198K – 2989
2021
Q1 		$198K Sell
3,593
-232
-6% -$15.4K ﹤0.01% 2832
2020
Q4 		$278K Buy
3,825
+347
+10% +$40.7K ﹤0.01% 2700
2020
Q3 		$686K Sell
3,478
-634
-15% -$160K ﹤0.01% 2150
2020
Q2 		$1.15M Buy
4,112
+417
+11% +$97.3K ﹤0.01% 1988
2020
Q1 		$658K Buy
3,695
+718
+24% +$154K ﹤0.01% 2052
2019
Q4 		$731K Buy
2,977
+65
+2% +$12K ﹤0.01% 2216
2019
Q3 		$343K Buy
2,912
+223
+8% +$33.7K ﹤0.01% 2510
2019
Q2 		$435K Buy
2,689
+403
+18% +$76.6K ﹤0.01% 2415
2019
Q1 		$540K Sell
2,286
-26
-1% -$6.58K ﹤0.01% 2300
2018
Q4 		$628K Buy
2,312
+800
+53% +$231K ﹤0.01% 2192
2018
Q3 		$674K Buy
1,512
+133
+10% +$62.3K ﹤0.01% 2167
2018
Q2 		$649K Buy
1,379
+119
+9% +$62.9K ﹤0.01% 2199
2018
Q1 		$743K Buy
1,260
+190
+18% +$118K ﹤0.01% 2067
2017
Q4 		$581K Sell
1,070
-175
-14% -$79.2K ﹤0.01% 2177
2017
Q3 		$522K Buy
1,245
+15
+1% +$4.6K ﹤0.01% 2288
2017
Q2 		$305K Buy
+1,230
New +$346K ﹤0.01% 2542
2016
Q2 		– Sell
-1,184
Closed -$71K – 2986
2016
Q1 		$71K Buy
1,184
+7
+0.6% +$468 ﹤0.01% 2937
2015
Q4 		$106K Buy
1,177
+117
+11% +$12.7K ﹤0.01% 2946
2015
Q3 		$122K Buy
1,060
+132
+14% +$23.2K ﹤0.01% 2912
2015
Q2 		$214K Buy
+928
New +$179K ﹤0.01% 2854

Other funds holding ASMB

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

RhumbLine Advisers's ASMB Position: Q1 2026 in Review

RhumbLine Advisers held its Assembly Biosciences (ASMB) position steady in Q1 2026 at 190 shares worth $5.27K. The position accounts for ﹤0.01% of the portfolio, ranked #3874.

RhumbLine Advisers first reported a position in ASMB in Q2 2015 and has held it in 32 quarters since. The position peaked at $1.15M in Q2 2020. 75 funds tracked by Wall St. Rank hold ASMB as of Q1 2026.

  • RhumbLine Advisers held 190 shares of Assembly Biosciences worth $5.27K as of Q1 2026.
  • RhumbLine Advisers left its Assembly Biosciences share count unchanged in Q1 2026.
  • Assembly Biosciences made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #3874 holding.
  • RhumbLine Advisers first reported a position in Assembly Biosciences in Q2 2015 and has held it in 32 quarters since.
  • RhumbLine Advisers's Assembly Biosciences position peaked at $1.15M in Q2 2020.
  • 75 funds tracked by Wall St. Rank held Assembly Biosciences as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.